Alcista
$70.33
Precio del escenario
$43.020
-0.310 (-0.72%)Al cierre
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
Currently, Alexandria Real Estate Equities Inc (ARE) is not a strong buy. The current price is $43.02, which is below the median analyst price target of $52.50, indicating potential upside. However, the RSI is at 47.099, suggesting a neutral momentum, and the stock has a high forward P/E of 16.6945, which may indicate overvaluation given the company's recent performance. The main risk is the significant decline in stock price over the past year, down 44.75%, reflecting ongoing challenges in the market.
BMO Capital
$41
2026-10-12
BMO Capital
2026-10-12
Precio objetivo
$41
JPMorgan
$56
2026-09-24
JPMorgan
2026-09-24
Precio objetivo
$56
Evercore ISI
$59
2026-09-21
Evercore ISI
2026-09-21
Precio objetivo
$59
Baird
$52
2026-08-24
Baird
2026-08-24
Precio objetivo
$52
BofA
$55
2026-08-24
BofA
2026-08-24
Precio objetivo
$55
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Alexandria Real Estate Closes $5 Billion Credit Facility

Alexandria Real Estate Closes $5 Billion Credit Facility

REITs Yielding 5.3% to 12.3% Attract Investors Amid Rate Hikes

Alexandria Real Estate Executive Sells Shares

Alexandria Real Estate Executive Sells 10,000 Shares
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).
Currently, Alexandria Real Estate Equities Inc (ARE) is not a strong buy. The current price is $43.02, which is below the median analyst price target of $52.50, indicating potential upside. However, the RSI is at 47.099, suggesting a neutral momentum, and the stock has a high forward P/E of 16.6945, which may indicate overvaluation given the company's recent performance. The main risk is the significant decline in stock price over the past year, down 44.75%, reflecting ongoing challenges in the market.
12 analysts cover ARE: 7 rate it Buy, 5 Hold and 0 Sell. The average price target is 56.85.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.